Медикаментозная терапия больных ишемической болезнью сердца в сочетании с фибрилляцией предсердий в реальной медицинской практике (результаты регистра РЕКВАЗА ФП-Курск)

The article considers the questions of drug therapy with statins, β-blockers, angiotensin converting enzyme inhibitors / sartans and oral anticoagulants in patients with coronary heart disease (CHD) in combination with atrial fibrillation (AF) at various stages of treatment according to the data of the RECVASA AF-Kursk registry. It is shown that, in comparison with the prehospital stage, the rate of prescribing these groups of drugs on discharging from hospital has increased, but has not significantly changed at the post-hospital stage and is not fully implemented. Moreover at the hospital stage, there was an insufficient achievement of target parameters of the lipid profile, heart rate and INR after treating with statins, β-blockers and warfarin, respectively. That is why, more adequate correction of risk factors and compliance with clinical recommendations in patients with CHD in combination with AF are required.